So big but so what? Innovent’s license deal fails to excite investors
The Chinese biotech is selling some cancer drug rights to a Japanese pharma giant for up to $11.4 billion, pocketing a big downpayment, so why did its stock price fall?…
Recent Articles
RELATED ARTICLES
-
Precision cancer drugs show promise for Kelun-Biotech
6990.HK -
3SBio hits the big time with $6 billion cancer drug deal
1530.HK
-
InnoCare licensing deal flops due to lack of upfront cash
9969.HK 688428.SHG
-
XtalPi scores landmark deal for AI drug discovery
2228.HK
-
RemeGen’s $4.2 billion licensing deal falls flat with investors
9995.HK 688331.SHG
-
HBM notches up another mega deal but is the model sustainable?
2142.HK
- Obesity drug maker Sciwind targets IPO, with heavyweight backers
